Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

BlueSphere Bio, a US-based immunotherapy spinout of University of Pittsburgh (Pitt), attracted $45.6m in series B funding last month, the Pittsburgh Business Times has reported citing a regulatory filing.
The company is targeting a $105m close and will use the capital to further develop its immunotherapy platform, called TCXpress, that is aimed at diseases such as cancer. Its lead asset aims to boost patient outcomes in bone marrow transplants.
TCXpress is based on technology developed by chief…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in